期刊文献+

氨氯地平联合缬沙坦治疗高血压合并糖尿病的效果及其对肾功能的影响

Efficacy of Amlodipine combined with Valsartan on Treatment of Hypertension with Diabetes and its Effect on Renal Function
下载PDF
导出
摘要 目的探究氨氯地平联合缬沙坦治疗高血压合并糖尿病的效果及其对肾功能的影响。方法选择2015年4月~2016年11月我院收治的141例原发高血压合并糖尿病患者,根据治疗方式不同分为三组,每组47例。A组予以氨氯地平治疗,B组予以缬沙坦治疗,C组予以氨氯地平联合缬沙坦治疗。治疗后,比较三组肾功能水平、血压以及血糖水平。结果与C组相比,A组和B组舒张压和收缩压水平均明显提高,差异有统计学意义(P<0.05);C组空腹胰岛素和空腹血糖水平与A组和B组相比下降显著,差异有统计学意义(P<0.05);A组和B组的微量尿白蛋白排泄率(UAER)和24h尿蛋白定量水平均高于C组,差异有统计学意义(P<0.05)。结论对原发高血压合并糖尿病患者应用氨氯地平联合缬沙坦治疗,能起到降压与降糖效果,可较好的保护患者的肾功能。 Objective To investigate the clinical efficacy of amlodipine combined with valsartan on treatment of hypertension with diabetes and its effect on renal function.Methods: Totally, 141 patients with essential hypertension and diabetes were admitted and treated in our hospital from April 2015 to November 2016. They were randomly divided into three groups with 47 patients in each group, A group (treatment with amlodipine), B group (treatment with valsartan), and C group (treatment with amlodipine and valsartan). After treatment, the renal function, blood pressure, and blood glucose were compared. Results: Comparing with A group and B group, the diastolic pressure, systolic pressure, festing insulin and fksting blood_glucose,urinary albumin excretion rate (UAER), 24h urine protein excretion were significantly decreased in C group (P 〈 0.05). Condusions: Application of amlodipine combined with valsartan on patients with essential hypertension and diabetes can achieve good results in anti-hypertension and anti- blood-glucose, protect renal function.
作者 何敏
出处 《西藏医药》 2017年第4期37-39,共3页 Tibetan Medicine
关键词 氨氯地平 缬沙坦 原发高血压 糖尿病 Amlodipine Valsartan Essential Hypertension Diabetes
  • 相关文献

参考文献8

二级参考文献86

  • 1于华.苯磺酸左旋氨氯地平联用卡托普利治疗老年高血压病70例疗效观察[J].中国现代药物应用,2009,3(5):88-89. 被引量:8
  • 2王芹.厄贝沙坦联合氨氯地平治疗老年晨峰高血压的临床研究[J].实用老年医学,2013,27(2):140-143. 被引量:5
  • 3陈炜,唐晓鸿.肥胖性高血压肾交感神经激活机制研究进展[J].生理科学进展,2013,44(6):433-436. 被引量:8
  • 4中国高血压防治指南修订委员会.中国高血压防治指南[M].2010年修订版.北京:人民卫生出版社,2011:31-31.
  • 5李光伟,陈家伦,宋怀东.胰岛素抵抗和胰岛8细胞功能评估[M]//胡仁明.内分泌代谢病临床新技术.北京:人民军医出版社,2003:423.
  • 6Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure,glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome[J]. Hypertens Res, 2008,31 ( 5 ) : 921.
  • 7GinsbergHN. Insulin resistance and cardiovascular disease[J]. Clin Invest,2002,106(5):453.
  • 8Prasad A, Quyyumi AA. Renin- angiotensin system and angioten- sin receptor blockers in the metabolic syndrorne[J]. Circulation, 2004,110:1507 - 1512.
  • 9Henriksen EJ ,Jacob S, Kinnick TR, et al. ACE inhibition and glu- cose transport in insulin resistant muscle:Roles of bradykinin and nitric oxide[J]. Am J Physiol, 1999,277( 1Pt 2) ,332.
  • 10Usuf S, Sleight P, Pogue J, et al. Effects of an angiotensin conver- ting enzyme inhibitor, ramipril, on cardiovascular events in high- risk patients. The heart outcome prevention evaluation study in- vestigators[J]. N Engl J Med,2000,342(3) :145 - 153.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部